Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

To lower cancer risks, a hepatologist, Dr Philips, suggests sous-vide cooking and marinating meats. He emphasises avoiding ...

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of ...

Dodgers outfielder Andy Pages left his native Cuba to pursue his baseball dreams, and he's making the most of the opportunity ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following state ...

Doctors and researchers are exploring various approaches to tackle this pervasive health issue, from new medications to dietary interventions. But what if one of the most promising treatments relies ...